

A rational approach to heparins

Citation for published version (APA):

Hemker, H. C., & Beguin, S. (1992). A rational approach to heparins. *Nouvelle revue française d'hématologie*, 34, 5-9.

Document status and date:

Published: 01/01/1992

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

General reviews

A rational approach to heparins

HC Hemker and S Béguin

Cardiovascular Research Institute, Department of Biochemistry, University of Limburg, P.O. Box 616, NL-6200 MD Maastricht, The Netherlands

Abstract. *It is shown why the current practice of expressing heparin activity in International Units is not an adequate way to deal with the situation that arises after injection of low molecular weight heparins. An alternative approach is proposed. It is taken into account that the fraction of a low molecular heparin that binds with high affinity to antithrombin III contains two fundamentally different components : the material above the critical chainlength of 17 sugar units that has both anti-factor Xa activity and antithrombin activity (ACLM) and the material below that length with anti-factor Xa activity only (BCLM). It is shown how the levels of ACLM and BCLM in a plasma sample can be determined and expressed in µg/ml.*

Une approche rationnelle des héparines

Résumé. *Il est démontré que la pratique habituelle d'exprimer l'activité de l'héparine en Unités Internationales n'est pas une façon adéquate de répondre à la situation qui fait suite à l'injection des héparines de bas poids moléculaire. Une autre méthode est proposée. Elle tient compte du fait que la fraction d'une héparine de bas poids moléculaire qui se lie avec une forte affinité à l'antithrombine III contient deux composants radicalement différents : celui dont la longueur de la chaîne est*

supérieure à 17 unités monosaccharidiques a une activité anti-facteur Xa et antithrombine et celui dont la longueur est inférieure et qui ne possède qu'une activité anti-facteur Xa. On démontre comment ces deux activités peuvent être mesurées dans un échantillon de plasma et exprimées en µg/ml.

Key words : (Low molecular weight) heparin — Antithrombin activity — Antithrombin III — Anti-factor Xa activity — Pentasaccharide

It is not necessary for an efficient treatment to be based on rational reasoning, nor will a therapy automatically follow from sufficient scientific knowledge of a disease. Psychotherapy has its therapeutic successes even though Popper explains us that no hard science is involved and no cure for AIDS has as yet evolved despite our detailed knowledge of its cause. That is what makes the difference between the art of the doctor and the science of medicine.

Yet there is a supreme reason for trying to push medicine as far as possible in the direction of the natural sciences : reproducibility. The failure of an ununderstood therapy may be due to any reason, from fundamental misconception (e.g. homeopathy) to stochastic variation, and trial and error is the only way to improvement. The failure of a therapy with a sound scientific basis is open to analysis and allows a design for amelioration.

For many years and up to the present moment the

effectiveness of heparin therapy has been recognised but not understood. A role of the anticoagulant action of heparin is our savest guess. Indeed the evidence for a central role of thrombin formation in the genesis of thrombosis is becoming overwhelming. If not recent research had shown how intricately platelet physiology is related to thrombin formation, it would hardly have been elegant to stress this point in an article dedicated to a scientist who has so ardently devoted his career to the blood platelet.


If we want to test the hypothesis that the anticoagulant action of heparin is the therapeutic one, then correct quantitation of this effect is the first requirement. This is a field fraught with difficulties, to some of which we think to have found rational solutions recently.

As long as unfractionated heparin was the unique species available the quantitation of its effects was relatively straightforward because in the different preparations the ratio of the different activities was fairly constant. Hence, if one measured e.g. an anti-factor Xa (aXa) dependent *ex vivo* test, it would correlate with any antithrombin (aIIa) dependent *in vivo* π P effect, because there was a fixed relation between the two activities. With the advent of low molecular heparins however, it became possible to vary the aXa- and aIIa activities independently in different heparin preparations. The convenient covariation of the two different anticoagulant activities was lost. Yet quantification continued to be carried out in terms of one biological effect only, often the anti-factor Xa activity, alternatively the aPTT, the heptest, the thrombin time etc. The carry over, onto low molecular weight heparins, of habits that were satisfying for unfractionated heparins, has been at the basis of much confusion. At this moment, based on the insights from recent research, it seems possible to design a more rational approach.

The biochemical basis of heparin action

The biochemical basis of heparin action is the fact that it catalyzes the inactivation of proteases by inhibitors available in the plasma.

As an example we take the inactivation of factor Xa (F.Xa) by antithrombin III (AT III).



Usually there is much more AT III than FXa so that the final concentration of this reactant will not be very different from the starting concentration¹. Therefore the reaction will obey pseudo first order kinetics i.e. the reaction velocity (*v*) is proportional to the initial concentration of AT III and the temporal concentration of F.Xa. Element-

tary reaction kinetics learns that in this situation F.Xa activity will disappear logarithmically. That is to say that its inactivation is characterized by a half-life time ($t_{1/2}$) that is inversely proportional to the reaction constant (*k*) and to the initial concentration of AT III. The AT III concentration multiplied by *k* governs the rate of decay of enzyme activity. It therefore is often referred to as the decay constant: k_{dec} . The dimension of k_{dec} is the inverse minute, because it is proportional to the inverse of the half-life time measured in minutes².

In order to be active in catalysing AT III mediated reactions, heparin has to contain the specific pentasaccharide through which the binding to AT III is mediated [6]. Additionally for catalysing the inhibition of thrombin it is necessary that the chainlength is not shorter than 18 monosaccharide units [1, 2, 7-9, 14, 18, 19]. In every heparin preparation one can therefore distinguish the high affinity material (HAM), that contains the pentasaccharide versus the low affinity material (LAM) that does not. Within the HAM fraction one can again distinguish between the material above the critical chainlength (ACLM) that is able to act on both thrombin and factor Xa inactivation, and the material below the critical chainlength (BCLM) that only acts on factor Xa [5, 12]. One can determine the *specific anti-factor Xa activity of a heparin*, which is the increase of k_{dec} of factor Xa brought about *in plasma* by 1 $\mu\text{g/ml}$ reaction medium of the heparin in question. One can also determine the *specific antithrombin activity of a heparin*, which, analogously, is the increase of the k_{dec} of thrombin *in plasma* brought about by 1 $\mu\text{g/ml}$ of the heparin [12]. Because k_{dec} is proportional to the concentration of AT III it should be normalised to plasma containing 1 μM of AT III by dividing it through the actual AT III concentration of the plasma used.

The specific anti-factor Xa activity is caused by the HAM molecules, the specific antithrombin activity by the ACLM molecules. Later we will discuss what else influences these constants.

Studying a large series of different heparins, we found that the specific activities of all ACLM prepara-

¹ This holds at any given instant during the clotting of blood when free F.Xa (and thrombin) is available. The peak F.Xa concentration in clotting plasma is ~20 nM, that of thrombin ~300 nM, whereas AT III is present at concentrations > 2 μM . It does not mean that the concentration of AT III remains constant during the whole of the clotting process. In serum the AT III concentration will equal roughly the AT III concentration of plasma minus the prothrombin concentration of plasma

² The relevant formulas are $C_t = C_o \cdot e^{k_{\text{dec}} \cdot t}$ or $\ln C_t = \ln C_o - k_{\text{dec}} \cdot t$. $k_{\text{dec}} = k \cdot [\text{AT III}]$. From this it follows that the half-life time $t_{1/2} = \ln 2 / k_{\text{dec}}$. The first formula can also be written as $C_t = C_o \cdot (1/2)^{t/t_{1/2}}$, which immediately shows the relation between half-life time and semilogarithmic decay

tions, obtained from different types of LMWH, vary within narrow limits, both with regard to the aIIa and to the aXa activity (e.g. the specific aIIa in the ACLM fractions of ten different LMWH preparations was found to be $14.1 \pm 2.7 \text{ min}^{-1} / (\mu\text{g/ml}) / \mu\text{M AT III}$ (calculated from data in [11]). The same holds for the specific aXa activity of the BCLM preparations. This means that the differences between different heparins are primarily due to their HAM, ACLM and BCLM content.

It is interesting to see that ACLM is more potent than BCLM is. In a mixture ACLM will as a rule overshadow the activities of BCLM, unless the proportion of BCLM becomes very large. This is the explanation of the observation that most LMWHs, like UFH inhibit free thrombin in clotting blood primarily by scavenging thrombin already formed, the inhibition of prothrombin conversion being much less important [10]. This group of heparins we called S (standard UFH-like) heparins. Only those preparations that do not or hardly contain ACLM, will act via inhibition of prothrombin conversion. We called them P (pentasaccharide-like) heparins [10].

Although in vitro BCLM is much less potent than ACLM, it may gain in importance in vivo. In the first place platelet factor 4 (PF4), released from activated platelets can completely neutralise ACLM but will not inactivate BCLM as thoroughly [14]. In the second place the biological half-life time in the circulation is shorter the longer the chainlength is. Therefore BCLM survives longer in the circulation than ACLM. After injection there is a "heparin fractionation in vivo that favours the persistence of BCLM molecules [12].

How to determine ACLM and BCLM levels in plasma

In plasma the aXa activity and the antithrombin activity can be readily determined. If the specific activities of the heparin injected are known one can readily obtain the ACLM level by deviding the increase of the k_{dec} of thrombin caused by the heparin through the specific antithrombin activity of that heparin [12]. One should be aware of the fact that in this way one measures the amount of ACLM molecules active in the plasma, i.e. bound to AT III. As we will see later this is not automatically the same as the concentration of those molecules in the plasma. Here it suffices to say that it is anyhow the *active* concentration. The level of all active HAM molecules is obtained by deviding the increase of the k_{dec} of factor Xa by the specific anti-factor Xa activity. The level of BCLM can then be obtained by subtraction of the HAM level and the ACLM level [12]. Preliminary results show that, after subcutaneous injection, ACLM disappears with a higher velocity than BCLM. This alone

makes it clear that the pharmacology of a LMWH cannot be treated as the pharmacology of one single chemical species and that it is necessary to at least recognise the two species mentioned. This however raises the question : is this sufficient or are there additional complications ?

Is it necessary to reckon with other effects ?

Other clotting factors and inhibitors

In plasma there are more clotting proteases than only thrombin and factor Xa and there is at least one more heparin-dependent inhibitor. Yet, in our opinion, in a first attempt to rationalisation, we may probably restrict ourselves to two variables that we discussed above.

Although the factors of the contact system are not insensitive to heparin action [17], the effect of the normal doses of heparin on this system are negligible and can for all practical purposes be disregarded if we restrict ourselves to the effects of prophylactic and therapeutic heparin concentrations [15].

Factor IXa is stable in plasma until heparins are added [16]. This anti-factor IXa effect contributes significantly to the anticoagulant effect of heparin in the intrinsic system [4]. We did not yet investigate LMWHs in this respect. The available data [13] suggest that the Mw dependency of the aIXa action is identical to that of the aIIa activity. If this is true, then there is no need for a separate consideration of the aIXa effect if one wants to quantitate the heparin effect because it will covariate, and therefore be adequately rendered by the antithrombin effect.

Heparin cofactor II (HC II) is an inhibitor of thrombin only, that is stimulated by heparin. Tenfold higher concentrations of heparin are however needed for this factor than for AT III [20]. Again the effect of this factor may be disregarded unless very high doses of heparin are given (e.g. artificial circulation).

Heparin binding proteins

In plasma AT III is not the only heparin binding protein (HBP). Histidine rich glycoprotein and many other plasma proteins compete with AT III for circulating heparin. This explains why the effect of heparin is proportional to the concentration of AT III, even though AT III ($\sim 2 \mu\text{M}$) is present in large excess over the highest possible concentration of heparin ($1 \text{ U/ml} \approx 0.3 \mu\text{M}$). In a purified system this would lead to practically complete binding of all heparin and adding more AT III would not appreciably change the situation. In plasma, with much competing proteins present, increasing (decreasing) the concentration of AT III will proportionally ameliorate (worsen)

its position in the competition.

The binding to the other proteins is however not via the specific pentasaccharide of the heparin. This means that it must be possible to set free anticoagulant heparin from heparin binding proteins by adding non-anticoagulant, low affinity heparin (LAM). A rough estimate tells that about 40 % of the potentially active heparin indeed binds to AT III. The active concentration of HAM, calculated by the procedures mentioned above is therefore 40 % of the real concentration.

The effect of platelets

Upon activation platelets release PF4, a protein that binds strongly to heparins. The maximal amount of PF4 released in normal platelet rich plasma (PRP) can neutralize some 0.4 U/ml of unfractionated heparin [3]. All ACLM can be readily inactivated by PF4 but BCLM binds with significantly lower affinity and cannot be inhibited completely. LMWHs therefore retain some activity, and especially BCLM, i.e. anti-factor Xa activity in the presence of activated platelets. What difference this makes as to their efficiency as antithrombotics is anybody's guess. One can imagine that in and around platelet rich thrombi, where the PF4 concentrations must be enormous, a LMWH that retains some of its activity should be more efficient than UFH. If this is true then the Choay pentasaccharide should be a more efficient antithrombotic than could be predicted from its anticoagulant action in platelet poor plasma. One can however also reason that the primary use of a heparin is to catch thrombin, so that no platelets are activated. If this is a valid reasoning, then ACLM would be a better preventive drug than BCLM, whereas BCLM would be better in curative situations.

Simple and composite effects of heparins

The simple and direct effects of heparin in plasma are the catalysis of thrombin and factor Xa inhibition. The catalysis of thrombin inhibition is simply a function of the amount of circulating ACLM and its specific activity. Factor Xa inhibition is a function of the total amount of active HAM, i.e. of both the ACLM and the BCLM concentration. If we denote the specific activities by S, with a subscript indicating the relevant factor, then :

$$aIIa = S_2 \cdot [ACLM] \text{ and} \quad (a)$$

$$aXa = S_{10} \cdot [ACLM] + S'_{10} \cdot [BCLM] \quad (b)$$

Above we discussed how these formulas can be used to obtain the ACLM and BCLM concentrations if the specific activities are known.

Any effect of heparin on a biological variable is a consequence of its aIIa and/or aXa action. For the sake of simplicity we assume the aXa action to be adequately rendered by the antithrombin action (see above). This means that e.g. the inhibition (prolongation) of the APTT (P(aptt)) is dependent upon both actions :

$$P(aptt) = p \cdot aIIa + q \cdot aXa \quad (c)$$

A combination of the above formulas (a, b and c) shows that :

$$P(aptt) = p' \cdot ACLM + q' \cdot BCLM \quad (d)$$

where p' and q' are combinations of p, q and the relevant specific activities. Because a pentasaccharide that has only aXa activity is a poor inhibitor of the APTT we can guess that p' is considerably greater than q' but further quantitation is impossible at the moment. This formula says simply that the outcome of a test like the APTT is dependent upon both the concentration of ACLM and of BCLM.

What holds for the APTT will hold for any other biological effect, but the coefficients (p' and q') will be different. If, e.g. we look at the inhibition of thrombus formation in a patient by heparin, it will again be a function of the ACLM and the BCLM concentrations, analogous to formula d. There is however no reason to assume that it will be precisely as dependent upon ACLM and BCLM concentrations as the APTT is. In other words, the coefficients (p' and q') in equation d will be different when this formula renders the APTT than when it is modified to render the antithrombotic action. The same will hold for the bleeding tendency caused by a heparin. Again the coefficients will differ from both those for the APTT and those for the antithrombotic activity.

It is even the bread and butter of heparin therapy that the coefficients for the bleeding tendency are smaller than those for antithrombotic action. This defines the therapeutic window. The clinically relevant coefficients will always be different from those governing the APTT or any other clotting test. Therefore any single *ex vivo* laboratory variable is incommensurable with antithrombotic or bleeding actions and it is fundamentally impossible to judge the effect of a heparin on basis of any single test only.

The approach that we propose is to determine ACLM and BCLM concentrations according to the principles exposed in previous paragraphs. Then we can relate antithrombotic and bleeding effects to those concentrations. In the meantime for a series of biological tests the dependence on ACLM and BCLM concentrations can be determined. That laboratory determination that reacts more or less in the same way as thrombosis inhibition or bleeding will then be the test of choice for routine monitoring of

patients. It may seem difficult to determine the influence of pure ACLM and BCLM on haemostasis and thrombosis, but this is not necessarily the case, because the high affinity fraction of unfractionated heparin is a good model for ACLM and the synthetic AT III binding pentasaccharide is a model for BCLM.

References

1. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Södenström G (1979) Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. *Thromb Res* 15 : 531-541
2. Barrowcliffe TW, Merton RE, Havercroft SJ, Thunberg L, Lindahl U, Thomas DP (1984) Anticoagulant activities of heparin oligosaccharides. *Thromb Res* 34 : 125-133
3. Béguin S, Lindhout T, Hemker HC (1989) The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma its inhibition by heparin. *Thromb Haemost* 61 : 25-29
4. Béguin S, Dol F, Hemker HC (1991) Factor IXa inhibition contributes to the heparin effect. *Thromb Haemostas* 66 : 306-309
5. Béguin S, Wielders S, Lormeau JC, Hemker HC (1992) The mode of action of CY216 and CY222 in plasma. *Thromb Haemostas* 67 : 33-41
6. Choay J, Petitou M, Lormeau JC, Synäi PJ, Casu B, Gatti G (1983) Structure activity relationship in heparin : a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. *Biochem Biophys Res Commun* 116 : 492-499
7. Danielson A, Raub E, Lindahl U, Björk I (1986) Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. *J Biol Chem* 261 : 15467-15473
8. Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U (1983) Binding of platelet factor 4 to heparin oligosaccharides. *Biochem J* 209 : 455-460
9. Ellis V, Scully MF, Kakkar VV (1986) The relative molecular mass dependence of the anti-factor Xa properties of heparin. *Biochem J* 238 : 329-323
10. Hemker HC (1987) The mode of action of heparin in plasma. In : Verstraeten M, Vermeylen M, Lijnen HR, Arnout J (eds) *Thrombosis and Haemostasis*. International Society on Thrombosis and Haemostasis. Leuven University Press, pp 17-36
11. Hemker HC, Béguin S (1991) The mode of action of heparins in vitro and in vivo. In : Lane D, Lindahl U (eds) *Heparin and related polysaccharides*. Plenum Press, New York
12. Hemker HC, Béguin S, Bendetowicz AV, Wielders S (1991) The determination of the levels of unfractionated and low molecular weight heparins in plasma. Their effect on thrombin mediated feedback reactions in vivo. Preliminary results on samples after subcutaneous injection. *Haemostasis* 27 : 258-272
13. Holmer E, Kurachi K, Soderstrom G (1981) The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor XIa, factor XIa and kallikrein by antithrombin. *Biochem J* 193 : 395-400
14. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U (1984) Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. *Biochem J* 218 : 725-732
15. McNeely TB, Griffith MJ (1985) The anticoagulant mechanism of action of heparin in contact-plasma : inhibition of factor X activation. *Blood* 65 : 1226-1231
16. Pieters J, Lindhout T, Willems G (1990) Heparin-stimulated inhibition of factor IXa generation and factor IXa neutralization in plasma. *Blood* 76 : 549-554
17. Soons H, Janssen-Claessen T, Tans G, Hemker HC (1987) Inhibition of factor XIa by antithrombin III. *Biochemistry* 26 : 4624-4629
18. Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U (1982) Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. *Thromb Haemostas* 47 : 244-248
19. Thunberg L, Lindahl U (1979) On the molecular-weight-dependence of the anticoagulant activity of heparin. *Biochem J* 181 : 241-243
20. Tollefsen DM (1984) Activation of heparin cofactor II by heparin and dermatan sulfate. *Nouv Rev Fr Hematol* 26 : 233-237

Received November 5, 1991 / Accepted November 29, 1991